2Seventy Bio
在场
高管
查看带有其 21 名主要高管的组织结构图
2Seventy Bio 搜索最多的简介
高管在2Seventy Bio变化
- Charles Newton已作为Director加入公司 (新闻发布的2024三月21号).
- Eli Casdin已作为Director加入公司 (新闻发布的2024三月21号).
- William Baird 曾任 Chief Financial Officer, 现任 Chief Operating Officer (新闻发布的2023九月13号).
创建提醒
跟踪 2Seventy Bio 的高管变动
生物技术
2Seventy Bio 拥有 2,281 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
2Seventy Bio 的最新新闻稿
- 2seventy bio to Participate in Upcoming Investor Conferences | 2seventy Bio
- News Releases | 2seventy Bio
- 2seventy bio to Participate in Upcoming Investor Conferences | 2seventy Bio
- 2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference | 2seventy Bio
- 2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference | 2seventy Bio
- 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress | 2seventy Bio
- 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress | 2seventy Bio
- 2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting | 2seventy Bio
- 2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting | 2seventy Bio
- 2seventy bio to Participate in CG Horizons in Oncology Virtual Conference | 2seventy Bio
- View more press releases Close
关于 2Seventy Bio 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Eli Casdin 
